Divi's Laboratories · NSE: DIVISLAB · BSE: 532488
Q2 FY21 results · Jul–Sep 2020
Divi's Laboratories reported revenue from operations of ₹1,749.30 crore (up 21.0% from Q2 FY20) and net profit of ₹519.59 crore (up 45.6% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,749.30 | 1,445.57 | +21.0% | 1,730.47 | +1.1% |
| Other income | 13.64 | 47.03 | −71.0% | 17.33 | −21.3% |
| Total income | 1,762.94 | 1,492.60 | +18.1% | 1,747.80 | +0.9% |
| Profit before tax | 693.49 | 487.87 | +42.1% | 660.98 | +4.9% |
| Net profit for the period | 519.59 | 356.78 | +45.6% | 492.06 | +5.6% |
| EPS, basic (₹) | 19.57 | 13.44 | +45.6% | 18.54 | +5.6% |
| Net margin (%) | 29.7 | 24.7 | 28.4 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,713.78 | 1,403.92 | +22.1% | 1,709.96 | +0.2% |
| Other income | 13.64 | 47.36 | −71.2% | 17.87 | −23.7% |
| Total income | 1,727.42 | 1,451.28 | +19.0% | 1,727.83 | −0.0% |
| Profit before tax | 685.03 | 483.02 | +41.8% | 660.70 | +3.7% |
| Net profit for the period | 513.30 | 352.83 | +45.5% | 492.25 | +4.3% |
| EPS, basic (₹) | 19.34 | 13.29 | +45.5% | 18.54 | +4.3% |
| Net margin (%) | 30.0 | 25.1 | 28.8 |
Consolidated
- Filed with BSE
- 07 Nov 2020, 19:12 IST
- Board meeting
- 07 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Nov 2020, 19:12 IST
- Board meeting
- 07 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE